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The development of new treatments for lung dis- 
ease is a subject of considerable interest to basic 
scientists, clinical scientists, pharmaceutical com- 
panies and practising chest physicians. It was, there- 
fore, appropriate that this should be the topic of the 
British Association for Lung Research (BALR) 
Symposium at the 1994 Winter meeting of the British 
Thoracic Society. The intention of the meeting organ- 
izer, Dr Noel Snell (Allen & Hanburys, Uxbridge), 
was to bring together scientist and clinician to 
exchange ideas pertinent to better therapy of a range 
of lung diseases, including respiratory virus infection, 
tuberculosis, cystic fibrosis, emphysema, asthma and 
lung fibrosis. The following article is not intended to 
provide an extensive review of the different topics of 
the symposium, but represents our interpretation of 
what was said on the day, both by the speakers and in 
discussion points raised from the floor. As such, it 
should be of use to the general reader seeking an 
update on development of new treatments for lung 
disease. In an attempt to limit the size of the article 
and keep it up-to-date, apart from a few pertinent 
citations, we have restricted the bibliography to 1990 
onwards. 
The Drug Development Process 
Drug development is something of a mystery to 
those of us outside the pharmaceutical industry, and 
so it was with great interest that the packed audience 
settled down to learn about the process from Dr 
Malcolm Johnson (Glaxo Research and Develop- 
ment, Uxbridge). Development of a new drug is a 
long, costly, high-risk venture which takes 12 yr and 
costs f 150 million (1,2). In the U.K., term of patent is 
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20 yr (17 yr in the U.S.A). As patent is granted in 
most countries to the first to file an application for 
the invention, patent applications are filed very early 
in the development of a drug. Thus it is usual that, 
once marketed, a drug may only have 8 yr of its 
patent left to run before expiry and the possibility 
that generic versions of the drug can immediately 
enter the marketplace and reduce sales of the inno- 
vator medication. Of 4000 compounds originally 
synthesized, only one reaches the market. Only one in 
five potential new drugs tested in humans is ever 
approved, and only one in three drugs reaching the 
market recoups development costs. Rejection of 
drugs can be due to poor pharmacokinetics or bio- 
availability, because they are unsafe or ineffective, 
do not offer advantages over existing marketed 
products, or because of difficulties in scaling-up from 
pilot plant to full production. The return on invest- 
ment of the very few commercially successful drugs, 
for example Zantac, has to offset the cost of less 
commercially successful drugs, as well as those com- 
pounds which do not make it through the develop- 
ment process, and also fund further research and 
development (R&D) (3). The current enormous cost 
to bring just one drug to the market is largely due to 
the complexity of new medical therapies, particularly 
for chronic diseases (e.g. asthma), and the develop- 
ment and regulatory review processes. Extensive 
delays contribute significantly to the cost and limit 
the time available to recover R&D costs. The drug 
research and development strategy is often in re- 
sponse to unmet medical needs and drug development 
strategies are changing dramatically to meet changing 
times, namely an aging population, new biotechnol- 
ogy enabling better diagnosis, and the demand for 
cures rather than palliative treatment. Drug com- 
panies need to maintain a ‘pipeline’ to launch new 
drugs either as patents expire or as drugs reach the 
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Fig. 1 The drug development process. In this simplified schematic, drug development is visualized as a series of linear 
processes running in parallel with sections overlapping. Alternative views are possible. Actual development is often more 
complex and involves parallel development programmes. Patent is filed early in the development of a compound and runs 
for 20 yr in the U.K. Final approval is achieved after N 12 yr, which leaves only 8 yr sales before expiry of patent. Phase 
I-III clinical studies increase in complexity and subject numbers. Phase IV studies gain further information about 
new indications, drug interactions, special disease states and patient populations, and cost effectiveness, and include 
post-marketing surveillance of the drug for safety updates and to detect any adverse events with low incidence. 
end of their usefulness. The pipeline also provides 
alternatives for lead compounds that may fail at some 
later point during the development process. 
New drugs can be discovered by serendipity (e.g. 
penicillin), by observation of potentially useful side- 
effects of other drugs (e.g. chlorpromazine as an 
antipsychotic, but originally intended to treat motion 
sickness), by investigation of the ingredients of folk 
medicine or Third World remedies (e.g. BN 52063, 
the active ingredient of the leaves of the Gingko tree 
which is used in a Chinese herbal remedy for chest 
tightness, and which proved to be an antagonist of 
platelet activating factor, PAF, a putative mediator 
of asthma), or by extensive screening programmes 
(e.g. most available anti-cancer drugs). Most 
recently, drugs have been discovered by hypothesis- 
driven rational drug design where useful information 
is gained much earlier in the development process. 
The latter methods are expensive and include 
targeted screening, molecular modelling, physio- 
pharmacologic in vitro models, and biotechnological 
techniques (4). 
The drug development process proceeds in a series 
of well-defined steps, many of which overlap and 
proceed in parallel (Fig. 1). For example, animal 
toxicological safety studies may continue far into the 
clinical trial period if the drug is to be given chroni- 
cally. Initial preclinical studies currently involve a 
battery of tests involving in vitro and in vivo exper- 
imental models to give general and specific infor- 
mation on pharmacology, pharmacokinetics and 
toxicology. Determination of ‘absorption, distribu- 
tion, metabolism and excretion’ (acronym ADME) is 
important in establishing margins of safety between 
therapeutic and toxic effects, in optimizing magni- 
tude, formulation and frequency of dosing, and in 
explaining differences in response. Preclinical testing 
takes, on average, 3.5 yr to complete for successful 
compounds, with only 1 in 1000 compounds advanc- 
ing to the next stage, Phase I clinical trials. Progress 
of a compound into clinical trials requires regulatory 
authority approval and detailed study protocols. The 
primary purpose of Phase I studies is to determine 
profiles for safety, pharmacokinetics (i.e. what the 
body does to the drug) and pharmacodynamics (i.e. 
what the drug does to the body). The study popu- 
lation is usually a small group of healthy young male 
volunteers. Phase I trials take approximately 1 yr, 
and one in three drugs fail at this stage. One of the 
goals of industry is to reduce the high failure rate in 
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Phase II by improving safety, pharmacokinetic and 
pharmacodynamic testing in Phase I. Phase II clinical 
studies are relatively short term, placebo-controlled, 
double-blind and randomized to determine dosage 
range and efficacy in a larger (n= lOO-500) but 
relatively homogeneous population of patients. Phase 
II trials take 2-5 yr with a 37% failure rate, either 
because the compound does not show the expected 
therapeutic effects in patients or, although safe and 
effective, does not appear to offer any substantial 
benefit over currently available medications. Phase 
III clinical trials of successful compounds from 
Phase II are multicentre, with a large (n= 100% 
3000) heterogenous population of patients. Despite 
making it to Phase III, one in three compounds 
fail at this stage. For successful drugs, marketing 
application is made to a regulatory authority (the 
Medicines Control Agency, M.C.A., in the U.K. 
or the Food and Drug Administration, F.D.A., in 
the U.S.A.), who essentially balance benefit with 
risk. The regulatory review varies markedly with 
country being approximately 6 months in France 
compared with 3 yr in Portugal. In the U.K. and 
U.S.A., review takes approximately 2.5 yr. With 
approval comes product launch, marketing and, 
importantly, post-market surveillance of adverse 
side-effects. 
Probably the most important studies currently on 
any drug, but also the most difficult to perform and 
interpret, are ‘pharmaco-economic’ studies which 
assess the overall value of a drug, not only to the 
patient, but also to society as a whole. It will be of 
interest in the future to observe how these consider- 
ations affect the direction pharmaceutical companies 
take in drug development. 
Treatments for Respiratory Tract Vial Infections 
Viruses are by far the commonest cause of respira- 
tory tract infections and are responsible for a range 
of symptoms including rhinitis, tracheitis, bronchio- 
litis and pneumonia. Viruses are the main cause of 
bronchiolitis and pneumonia in children under 5 
years of age, and are the cause of 50 million illnesses 
annually in the U.S.A. at a cost to society of an 
estimated $5 billion. Research into antivirals has 
hitherto been sluggish because most respiratory tract 
viral infections are comparatively mild and self- 
limiting, while most antivirals are toxic. Conse- 
quently the risk:benefit ratio was high. However, 
more severe forms of viral disease are currently being 
diagnosed in the lung, including cytomegalovirus 
and hantavirus ($6). Consequently, development 
of new antiviral therapies has become an important 
area of research, and was a topic tackled with 
vigour by Dr Noel Snell (Allen & Hanburys, 
Uxbridge). 
There are a number of important and well-defined 
viral pathogens relevant to the airways, namely res- 
piratory syncytial virus (RSV), parainfluenza virus, 
influenza A, B and C viruses, cytomegalovirus, 
human immunodeficiency virus (HIV), measles 
virus, varicella-zoster (chicken pox) virus, and rhino- 
virus which, conveniently, tend to exhibit similar 
epidemiology worldwide. For example, RSV and 
parainfluenza virus have a similar incidence in chil- 
dren with bronchiolitis in the U.S.A. and India of 65 
and 60%, and 14 and 21%, respectively, in those 
where a diagnosis has been made. Vaccination is 
unrealistic for the common cold because of its 
multiplicity of aetiological agents and serotypes. 
Vaccination has limited use for influenza because of 
periodic major antigenic shifts. 
In the development of antivirals, it is important to 
develop compounds with reduced systemic toxicity. 
In addition, influenza virus and many others disrupt 
cilia and new drugs should not be more ciliotoxic 
than the virus (7). Targeting helps limit systemic 
adverse side-effects, for example delivery by inhala- 
tion. Liposome encapsulation of nebulized drug may 
preserve antiviral efficacy whilst reducing host toxic- 
ity. Ribavirin, amantadine and interferon are more 
effective and probably safer when given by small- 
particle aerosols than when given systemically. 
Aerosol delivery of antivirals to ventilated patients, 
and with nasal continuous positive airway pressure 
(N-CPAP), is effective (8). 
Many antivirals have been developed, most of 
which have little or no clinical benefit, or may 
even exacerbate symptoms. Thus, despite pro- 
longed research programmes, few drugs have been 
developed which possess clinically useful activity 
against viral respiratory infections. Only two 
antivirals are currently approved for respiratory tract 
viral infections, namely amantadine for influenza A 
infections (but not B or C), and the nucleoside 
ribavirimtribavirin. Ribavirin is effective and well- 
tolerated in infections due to RSV (9) and influenza 
A and B. 
Prerequisites for initiation of clinical trials include 
characterization of development of viral resistance, 
determination of the toxicological profile of the 
drug and the most appropriate form of delivery. 
Selection of an appropriate animal model is impor- 
tant to ensure the relevance of the data to humans. 
Factors to be considered in the design of clinical 
trials for antivirals include: (i) whether to treat a 
syndrome or a specific infection; (ii) the population to 
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be examined (with the need to consider specificity); 
(iii) prophylactic vs. therapeutic administration; 
(iv) naturally-occuring or experimentally-induced 
infection; (v) entry of patients into the study, whether 
on clinical grounds or confirmed diagnosis; (vi) the 
route and regimen of drug administration; and 
(vii) the nature of the comparator medication. Study 
end-points are important and involve assessment 
of symptoms and signs of infection, magnitude of 
nasal secretion (by nose blowing into a standard 
tissue for weighing), the degree of nasal obstruction, 
presence of fever, use of antipyretics, analgesics 
or other therapy, duration of illness, and 
hospitalization. 
There are a number of strategies for development 
of antivirals including making the host epithelium 
resistant to the virus (interferon-a and -p), prevention 
of viral uncoating (dichloroflavan), and prevention of 
viral attachment (receptor antibodies, anti-ICAM-1). 
It may be possible to enhance host immunity, for 
example by immunomodulatory drugs such as 7-thia- 
8-oxoguanosine, which, unfortunately, is effective in 
rodents but not in humans (10). Relief of symptoms 
by inhibiting the effects of inflammatory mediators 
using glucocorticosteroids or nedocromil sodium has 
been found to have limited use. The recent obser- 
vation that interleukin (IL)-1 is increased in nasal 
secretions of symptomatic patients with rhinovirus 
colds compared with non-infected or asymptomatic 
controls may indicate a new line of therapy (11). 
There are also numerous empiric treatments includ- 
ing zinc lozenges, vitamin C and local heat which 
have yet to be proven effective (12). 
Duration of treatment and cost are additional 
limitations to effective antiviral therapy. Ideally, 
small respirable drug particles (median mass diam- 
eter 15 p) need to be delivered constantly from an 
aerosol nebulizer. In reality, the duration of delivery 
is often uncertain and may be required for up to 18 h. 
For ribavirin, 3 days treatment costs &585 which 
merits comparison of benefits over conventional 
therapy. However, ribavirin is cost-effective for 
short-term treatment if people are very ill. 
A new drug (4-guanidino Neu5Ac 2en: GR 121167) 
has been described (13) which is a novel viral neur- 
aminidase (sialidase) inhibitor and represents a new 
class of antiviral compound. The drug has selective 
activity against influenza A and B, and a volunteer 
study has shown it to be effective in both prophyaxis 
and treatment of experimental influenza A (H,N,) 
infection when administered intranasally, without 
appreciable adverse side-effects. GR 121167 is 1 OO- 
fold more effective than amantadine. Phase II clinical 
trials are in progress. 
Future Trends in Treatment of Tuberculosis 
Tuberculosis (TB) is the single largest killer in the 
world. Its incidence has stopped declining, and is now 
static or increasing in prevalence worldwide, causing 
the World Health Organization (WHO) to declare 
it a global emergency. ‘Standing-room only’ at 
Dr Peter Davies’ (Tuberculosis Research Unit, 
Liverpool) enthusiastic presentation on future trends 
in the treatment of tuberculosis attested to the 
renewed clinical importance of ‘consumption’. 
The increase in TB is due to several factors includ- 
ing the human immunodeficiency virus (HIV) epi- 
demic in Africa and parts of the U.S.A., increased 
immigration into the U.K., increased social depriva- 
tion (for example in the East End of London), and 
lack of follow-up of TB patients to determine effec- 
tiveness of treatment (14-16). Consequently, the inci- 
dence of TB in the U.K. is related to the ethnic 
composition of neighbours, being least with nationals 
and West Indians, and most with Africans and those 
from the Indian subcontinent. Cutbacks in research 
and expertise in this field in the developed nations, 
with lack of funding by governments and industry, 
has ensured that no new anti-TB drugs have been 
developed for over one-quarter of a century. The 
closing of the Medical Research Council’s (M.R.C.) 
TB unit was cited as a case in point. 
Some new antibiotics developed for other indica- 
tions are of value in treatment of TB, for example the 
quinolones. The use of multiple chemotherapy to 
treat TB is normal practice and drugs commonly 
employed include isoniazid, pyrazinamide, etham- 
butol, rifampicin, streptomycin and thiacetazone 
(14,16). Isoniazid may be considered the ‘Carling 
Black Label’ of antibiotics as it reduces organism 
number to one-hundredth of the original concentra- 
tion per day. In contrast, rifampicin is the ‘Heineken’ 
of antibiotics because it inhibits the slow-growing 
bacilli which other antibiotics cannot reach. The 
usefulness of this allegory was not wasted on the 
audience. Isoniazid and rifampicin provide first line 
defence, while streptomycin and pyrazinamide pro- 
vide second line defence. Thus, a two pronged attack 
is required-one to rapidly reduce bacterial cell 
numbers and the other to wipe out persistent organ- 
isms. Monotherapy is only effective for a short time, 
and leads to the development of resistant organisms. 
Adverse side-effects of chemotherapy are manifold, 
including nausea, skin irritation and pyrexia, and one 
needs to be careful about how patients take their 
‘cocktail’ of drugs (15). Wherever possible, patients 
must be observed to swallow drugs since non- 
compliance has risen because of the lengthy and 
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complex therapeutic regime of 2 months treatment 
with isoniazid, rifampicin, streptomycin and pyrazi- 
namide and another 4 months with isoniazid and 
rifampicin. Nevertheless, this is considerably shorter 
than previously, when patients underwent supervised 
drug therapy for 24 months, albeit, unlike today, 
usually with complete success. Where there is non- 
compliance, it is better to stop and recommence 
treatment using an appropriate regimen. An alterna- 
tive treatment regimen is also required if a patient is 
found to have developed resistance, which most often 
occurs with non-compliance or if the patient has had 
TB therapy previously. 
There are no strict guidelines in the U.K. concern- 
ing documentation of previous history of TB or 
treatment. This is important since thorough monitor- 
ing of previous TB would enable risk factors for 
drug resistance to be determined within the U.K. In 
contrast, in the U.S.A., monitoring of previously- 
affected patients is more effective and allows assess- 
ment of prevalence of drug resistance in the 
population. A serious drawback for the clinician is to 
know what will be the most appropriate drug therapy 
since it currently takes many weeks to determine 
the presence of (multi-) drug resistant organisms. The 
need for ‘fast track’ bacteriology to determine the 
best therapy was emphasized. The worst treatment is 
to add a single drug because this is highly likely to 
induce further drug resistance. One problem is that 
bacterial DNA levels are often so low that they are 
difficult to detect by conventional methods. However, 
PCR and other molecular biological techniques 
enable DNA amplification and detection, and char- 
acterization of bacteria obtained from tissue biopsies 
and lung secretions (17,18). From this the opportu- 
nity exists not only to rapidly identify the organism 
and the presence and nature of drug resistance, but 
also to perform epidemiological studies of transmis- 
sion. In the face of an increasing incidence of multi- 
drug resistant TB, new drugs are needed to reduce 
both the period of treatment and the development of 
drug resistance. New formulations are grossly under- 
studied and, therefore, not so easy to understand in 
terms of improving treatment. 
An alternative concept to antibiotics is immuno- 
therapy. This is not new. Heinrich Koch was the first 
to show that injection of inactive (old) tuberculin into 
rabbits could result in healing, but the outcome was 
inconsistant (19). The aim of immunotherapy is to 
replace an innappropriate immune response by an 
appropriate one. Those with TB lack the immune 
recognition of common mycobacterial antigens 
that most individuals exhibit. Immunotherapy 
with Mycobacterium vaccae restores this response, 
suggesting that this non-virulent organism may be 
useful in immunotherapy for TB. Indeed, there is 
increasing evidence that the cure rate of newly diag- 
nosed patients with TB treated with M. vaccae is 
improved (19). In addition, there are few side-effects 
and a single injection of killed M. vaccae may be 
sufficient in patients with short histories, while 
repeated injections may be needed in those with 
chronic disease and/or acquired resistance. 
New Treatments for Cystic Fibrosis: Gene Therapy 
and Recombinant Human DNase 
Cystic fibrosis (CF) is a common, lethal, general- 
ized exocrinopathy of which the lung involvement is 
the usual eventual cause of death, from respiratory 
failure (20). The lung disease results from poor 
airway defence against infection, starting as colon- 
ization in childhood and progressing to episodic 
infection and resultant lung damage. Cystic fibrosis is 
inherited as an autosomal recessive trait caused by 
mutations in the gene encoding the CF transmem- 
brane conductance regulator (CFTR) (21). CFTR 
functions as a chloride (Cl ~ ) channel in the apical 
membrane of the airways and gut, and elevations 
in intracellular cyclic adenosine monophosphate 
(CAMP) concentrations increase Cl ~ transport 
through CFTR. Transepithelial ion transport is 
linked to water transport and Cl- secretion may be 
one means of hydrating airway surface fluid. Defec- 
tive CFTR activity may, therefore, limit mucus 
hydration. Sodium (Na’) absorption, and thereby 
water absorption, is also increased in CF, which may 
further dehydrate the airways. Dehydrated airway 
fluid is less amenable to mucociliary clearance which 
may in turn encourage bacterial colonization and 
repeated infection. In Caucasians, one person in 25 
carries the abnormal gene which means that for 
approximately one couple in 625, both will be 
carriers. Improvements in paediatric care, physio- 
therapy, antibiotics and nutrition, and the establish- 
ment of special CF centres, has increased average 
survival from approximately 1 yr in the late 1930s to 
the present 30 years of age. Nevertheless, this is no 
great age and new technologies are now being 
explored to provide better therapy of this pernicious 
disease. Gene therapy and recombinant human 
DNase move treatment of CF into a new era. 
GENE THERAPY 
The cloning of the CFTR gene has made gene 
therapy for CF a realistic goal (22). However, 
Dr Duncan Geddes’ (Royal Brompton Hospital, 
London) measured presentation served to remind us 
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that over-optimism needs to be tempered by realism. 
The first consideration is whether gene therapy is 
necessary for CF, especially as improved con- 
ventional therapy has increased life expectancy so 
dramatically over the last few decades. However, 
many patients require drug treatment four times a 
day, in addition to a considerable time spent on 
physiotherapy. Disappointingly, the median pro- 
jected survival of 40 years of age for CF babies born 
in the 1990s (23) indicates that the rate of improve- 
ment and effectiveness of conventional therapy is 
plateauing. Pharmacological intervention using 
amiloride to reduce Na’ absorption and rehydrate 
the airways is being explored, although conflicting 
data have been reported (24,25). Thus, although 
incremental improvements in future therapy can 
be expected, there is a pressing need for the 
more effective and less intrusive treatment which 
gene therapy could provide. However, gene 
therapy is a young discipline and is fraught with 
uncertainties, often concerning the most basic of 
questions. 
An important issue concerns the target cells for 
gene transfer. The lungs are the most clinically 
relevant organs affected. Pathology begins in the 
bronchioles and moves proximally. Interestingly, in 
bronchi CFTR localizes predominantly to the sub- 
mucosal glands (26), whereas in the bronchioles and 
alveoli, where glands are absent, CFTR localizes to 
undefined populations of ciliated cells and non- 
ciliated secretory cells in the surface epithelium (27). 
The contribution to lung pathology of glandular 
CFTR requires clarification. Gland targeting would 
be difficult using topical application. Targeting the 
small airways would appear the better therapeutic 
option as these can be reached with conventional 
nebulizer technology. It is worth considering here 
that if the CF defect in the lungs is corrected and life 
expectancy increased, other organs (pancreas, gut) 
could become the clinical focus, leading to a further 
era of CFTR gene therapy. 
Another key issue is how much CFTR transfer is 
required for clinical benefit. Expression of CFTR 
mRNA and gene product in healthy airway epithelia 
is extremely low compared with a number of other 
epithelia, including kidney, sweat gland, pancreas 
and gut (28,29). Why CFTR malfunction is so fun- 
damental to pathogenesis in the organ with least 
expression is a conundrum that is currently un- 
explained. However, the low expression suggests that 
low transfer levels would be sufficient for therapy. It 
is estimated that as little as 10% of airway epithelial 
cells need to be corrected to produce marked changes 
in function. 
The requirements for transfer of the CFTR gene to 
cells are the same as for any gene transfer and include 
attaching a CFTR complimentary deoxyribonucleic 
acid (cDNA) plasmid to a promoter, both of which 
are then incorporated into a vector (also termed a 
gene transfer agent/vehicle; GTA/V) which is able to 
penetrate the cell and deliver the CFTR-promoter 
complex to the nucleus (22) (Fig. 2). In the first 
instance, ‘ubiquitous’ promoters, for example SV40, 
rather than cell-specific promoters are likely choices 
because of uncertainties concerning the target cell in 
CF. Short-acting promoters are not good because 
they lose efficacy with time. A number of vectors are 
currently available, although the main focus is on 
replication-deficient recombinant adenoviruses and 
cationic liposomes (22,30), each of which has certain 
advantages and disadvantages (Fig. 2). Future sys- 
tems may well combine the best features of both. The 
principal advantage of virus vectors is that viruses 
have evolved efficient systems to transfer genes to 
human cells, albeit that the host has had an equal 
time to develop systems to prevent viral gene trans- 
fer. Adenovirus is capable of efficiently transferring 
human CFTR cDNA to airway epithelial cells in a 
number of animal species, including humans. How- 
ever, there are concerns related to the safety and 
efficacy of adenovirus vectors. For example, although 
designed not to replicate, first generation adenovirus 
vectors may theoretically replicate by duplication or 
by recombination with a wild-type virus to produce a 
replication-competent virus. Adenovirus genes may 
also be expressed at low levels causing host cells to be 
targeted by virus-specific T-lymphocytes with conse- 
quent inflammation and destruction of the host’s 
cells. The magnitude of inflammation is directly 
related to ‘dose’ of virus administered. Additionally, 
the outer protein coat of the adenovirus may be 
immunogenic, which may limit repeat administra- 
tion. Nevertheless, adenovirus transfer of CFTR to 
the nasal mucosa of three CF patients transiently 
corrects the nasal epithelial Cl- transport defect 
(31). This study demonstrated that gene transfer 
could be achieved and represented a small step 
forward for gene therapy for CF. 
Liposome-mediated CFTR gene transfer to the 
nasal mucosa of nine CF patients also transiently 
corrected the nasal epithelial Cl- defect (32). Cati- 
onic liposome vectors, to which the DNA to be 
delivered is bound to the outer surface of the 
liposome by ionic interaction, are undoubtedly less 
efficient than adenovirus at transferring genes: prob- 
ably only one in 1000 cDNAs delivered to a host cell 
reaches the nucleus and is expressed. However, lipo- 
somes have low toxicity and, because they do not 
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Fig. 2 Gene transfer in cystic fibrosis (CF). CF transmembrane conductance regulator (CFTR) cDNA is linked to a 
promoter (P: A=poly-adenine tail) which is either incorporated into a virus or attached to a liposome (outside surface). 
Currently, two systems for transfer of the CFTR gene to airway epithelial cells are available, namely replication-deficient 
adenovirus vectors (left panel) or cationic liposomes (right panel). The virus interacts with the cell surface, enters an 
endosome and moves to the nucleus, shedding its viral coat, and delivers the gene. The process is relatively efficient. The 
viral DNA containing the CFTR cDNA functions epi-chromosomally to express CFTR protein. Disadvantages include 
development of humoral immunity (HI) against viral coat, induction of inflammatory mediators by interaction of vector 
proteins with target tissue, and T-cell cytotoxicity against low-level protein expression from the viral genome. Liposome- 
CFTR cDNA complexes fuse with the cell membrane after which the vast majority of the lipid and DNA is removed by 
lysosomes. Only a small proportion of CFTR cDNA reaches the nucleus with the theoretical disadvantages of induction of 
inflammation, toxicity from intracellular lipid accumulation and humoral immunity (HI) against CFTR DNA. Both 
delivery systems have been shown to increase Cl conductance in experimental systems and in human nasal mucosa in vivo. 
(Adapted and redrawn after 30). 
contain protein, are less likely than viruses to pro- most severely affected patients, and gene transfer to 
voke inflammation or initiate immune reactions to the relatively undamaged airways of children with 
repeat administration. Nevertheless, at the higher CF may prove a more successful option. The recent 
doses which may be required for administration to 
the lower respiratory tract, there is a possibility of 
toxicity from the excess lipid or DNA. 
The future of gene therapy for CF lies in CFTR 
gene transfer to the lower airways. This will be a 
more exacting task than delivery to the nasal mucosa 
of patients with mild disease (31,32). Nebulization 
gives widespread distribution with prolonged contact 
report of intravenous administration of an expression 
plasmid-liposome complex (33) indicates that other 
routes of gene transfer are possible. Airway epithelial 
cells turn over slowly and repeated treatments may 
be required to insert sufficient CFTR gene into the 
target cell population. Consequently, the duration of 
clinical benefit and, hence, frequency of CFTR 
administration are subjects of considerable debate. 
time if required, but may disrupt liposome vectors. Unlike nasal administration of CFTR gene, where 
The viscid mucus in the airways may prove too great there is access for in situ measurement of physiologi- 
a barrier for topically applied solutions, although cal end-points, for example nasal potential difference, 
physiotherapy before gene administration may measurement of end-points in the lung will not be so 
reduce this problem. It may be difficult to treat the easy. In addition, it is unclear what magnitude of 
12 BALR Symposium 
correction of the ion transport defect is required to 
demonstrate clinical benefit. Other, more clinically 
relevant end-points may be required, for example 
determination of Pseudomonas aeruginosa levels or 
mucus rheology. Changes in the latter parameters 
may only become apparent after repeated, rather 
than single-shot, treatment. Despite these problems, 
the quest for gene therapy for CF continues. Govern- 
ment advisory committees on gene therapy have been 
set up both in the U.K. and abroad to approve 
protocols and production standards, and at least 10 
phase I clinical trials are currently planned or under- 
way (22). Although the potential for gene therapy of 
CF has been demonstrated and progress has been 
remarkably rapid, it will undoubtedly take a number 
of years before a treatment of proven benefit to CF 
sufferers is developed. In the meantime, although 
there is room for cautious optimism, it would be 
unfair to raise the expectations of patients too 
high (34). 
RECOMBINANT HUMAN DNASE 
Whilst the potential for CFTR gene transfer is 
being explored, recombinant human DNase I (rhD- 
Nase) treatment may increase the life expectancy of 
CF sufferers so that they are eventually able to 
benefit from gene therapy. Dr Margaret Hodson 
(National Heart & Lung Institute, London) has 
been actively involved with clinical evaluation of 
DNase treatment for many years and she updated 
us on clinical trials with rhDNase, a novel treatment 
of CF. 
A prominent feature of pathology in CF is accu- 
mulation of purulent and viscid secretions in the 
airways. The mucociliary clearance mechanisms of 
the airways are compromised by these secretions 
and many patients have to undergo regular (twice 
daily) chest physiotherapy in order to clear their 
airways. DNA is present in high concentrations 
(3-12 mg ml - i) in the infected secretions. Neutro- 
phils predominate in the secretions, and it is the 
highly polymerized DNA released from the dead and 
dying neutrophils of the CF patient which contrib- 
utes to the raised viscosity of the secretions (35). 
Breaking up the DNA may, therefore, be a way of 
reducing the viscosity of the secretions. A number of 
uncontrolled studies in the 1950s and 1960s using 
bovine pancreatic DNase I, demonstrated sputum 
liquefaction but failed to demonstrate convincing 
clinical benefit. Of concern was the prevalence of 
adverse side-effects, probably due to a combi- 
nation of contaminating pancreatic proteases and 
incomplete (77%) homology of bovine and human 
DNase. 
The cloning, sequencing and expression of recom- 
binant human DNase (36) was designed to limit 
side-effects and also to avoid the development of 
antibodies to DNase. The rhDNase decreased the 
size of the DNA in CF sputum and rapidly increased 
the ‘pourability’ of the sputum. The latter point was 
graphically demonstrated in one of Dr Hodson’s 
slides which showed two inverted pots of CF sputum, 
one of which retained its viscid content, whilst from 
the other, treated with rhDNase, sputum flowed. 
Recombinant hDNase is formulated for human use 
as Pulmozyme (37) and clinical trials have been 
completed or are underway to determine its potential 
as therapy for CF. 
Two phase I dose-escalation studies in 12 and 16 
patients indicated that inhaled rhDNase was safe in 
CF patients and gave some clinical benefit (3839). 
Two phase II studies in larger groups of subjects (71 
and 181) with comparatively mild CF demonstrated 
that short-term (10 days administration) rhDNase 
was safe and resulted in improvements in FEV, 
(increased by l&15%), and in patient symptom 
scores and sense of wellbeing (40,41). The improve- 
m :’ + in pulmonary function declined when treatment 
WL. topped. Voice alteration (hoarseness) was the 
adverse side-effect causing greatest concern to the 
study participants. Improvements in FVC and 
dyspnoea scores varied between the two studies. The 
comparative success of the phase II trials has 
prompted large-scale phase III trials to assess efficacy 
of rhDNase. The first of these trials in 968 adults and 
children with mild to moderate CF treated for 24 
days demonstrated a reduced number of exacerba- 
tions of respiratory symptoms, and slightly improved 
lung function (42). The rhDNase was well tolerated, 
although again voice alteration and laryngitis were 
common symptoms, albeit comparatively mild and 
short-lasting. In all the studies above, patients in 
general had mild disease, where the greatest improve- 
ments might be expected. Further studies are now 
underway in more severely ill patients to evaluate the 
safety and efficacy of rhDNase when given at the time 
of pulmonary exacerbation (43) or in patients with 
severe pulmonary involvement (FVC 40% predicted) 
(41,44). These preliminary data look promising in 
terms of safety and efficacy. In a patient with lobar 
atelectasis, rhDNase markedly reduced sputum vis- 
cosity, leading to relief of airflow obstruction and 
partial resolution of the atelectasis (45). 
As befitting the importance of rhDNase as poten- 
tially imminent therapy for CF, Dr Hodson’s talk 
generated considerable discussion. In particular there 
was heated debate concerning the routine use of 
rhDNase in patients because of the possibility of 
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over-thinning the mucus so that the patient ‘drowns’. 
Good physiotherapy was essential to avoid this 
possibility. The contribution to improved lung func- 
tion in many of the studies of increasingly enthusias- 
tic physiotherapy as patients get better was also 
emphasized. The effect of rhDNase on areas of 
epithelium not protected with mucus was questioned. 
Another point was that, in an ideal world, inactivated 
rhDNase rather than just saline should be the con- 
trol, although it was acknowledged that rhDNase 
was an expensive commodity simply to inactivate. 
The cost of rhDNase therapy, currently estimated at 
&6000 per year, may prove prohibitive. However, 
improvements in production must reduce costs of 
rhDNase which, although not representing a replace- 
ment for current standard therapies, appears to be a 
safe and effective drug for improving lung function 
in CF. 
Alpha-l Antitrypsin Replacement Therapy 
Alpha- 1 antitrypsin deficiency is relatively com- 
mon, predicted to affect l-2% of the population, and 
positively related to the development of emphysema, 
particularly in cigarette smokers. Dr Robert Stockley 
put the problem into context, showing a slide of the 
original gel electrophoresis photographs illustrating 
serum protein patterns from normal and a-l- 
antitrypsin-deficient subjects who were, in fact, being 
studied for conditions unrelated to the lung (46). The 
location of a missing protein corresponded to an a-l 
band known to have antitryptic activity, a-l anti- 
trypsin, and the clinical condition is still referred to as 
a-l antitrypsin deficiency. In fact, we now know that 
this is a misnomer, since Travis and his co-workers 
subsequently showed that a-l antitrypsin preferen- 
tially binds to, and inhibits, neutrophil elastase (47). 
It is also known as a-l proteinase inhibitor and is a 
member of the serine proteinase inhibitor family 
(serpins). The normal M form and deficient variant Z 
form (see below) can be separated by electrophoresis 
on the basis of charge. The a-l antitrypsin gene is 
located on chromosome 14 and consists of approxi- 
mately 12 kbp divided in to seven exons and six 
introns, the transcription of which is governed by at 
least two promoters, one each for monocytes and 
hepatocytes, which are functional only in the relevant 
cells (for a description of the gene, its regulatory 
elements and alternative modes of transcription, see 
48). The reactive site of the protein is at methyl- 
serine residues 358-359 (it contains approximately 
400 amino acids), close to the carboxy terminal end 
of the molecule, the glycosylated protein having a 
molecular weight of about 52 kDa. The presence of 
the methionine residue is crucial, since oxidation 
of this residue modulates inhibitory activity via 
inactivation. Although, under physiological con- 
ditions, this enables neutrophil elastase to react 
appropriately, unwanted oxidation (e.g. due to 
cigarette smoke inhalation) may result in enhanced 
proteolysis. 
The deficiency, however, is not related directly to 
the activity of a-l antitrypsin, but rather to low levels 
of circulating protein which is primarily synthesized 
and secreted by the liver. A guanine to adenine 
transition in exon V results in a G1u342 to Lys342 
amino acid substitution (49). Despite this knowledge, 
the precise reason for accumulation of a-l antitrypsin 
in the liver exercised the minds of many researchers 
for years until Lomas et al. (50) established that the Z 
mutation results in molecular interaction between the 
reactive centre loop of one molecule and the gap in 
the A-sheet of another. Consequently, approximately 
85% of the u-l antitrypsin aggregates intracellularly, 
while the remaining monomeric form is secreted to 
provide only about 15% of the normal levels of 
circulating antiprotease. Since u-l antitrypsin perme- 
ates the pulmonary interstitium and secretions, and 
emphysematous human lung tissue contains elastin- 
bound neutrophil elastase proportional to the degree 
of emphysema (51) a threshold concentration of 
serum inhibitor is believed to exist below which 
proteolytic damage and emphysema occurs. Alpha-l 
antitrypsin replacement therapy aims to augment 
pulmonary antiprotease levels to above this threshold 
level. 
Alpha-l antitrypsin replacement therapy became 
possible when sufficient quantities of the partially 
purified serum protein (80% pure) became available 
(now called Prolastin, Bayer). The preparation is 
heat-inactivated but contains functional u-l anti- 
trypsin. Early studies aimed at intravenous infusion 
of the protein to achieve and maintain a threshold 
level of 800 mg l- ‘. This level is 35% of normal and 
has been determined from epidemiological studies 
(52,53). Normal serum levels are about 2.0-2.6 g 1~ ‘. 
Weekly or monthly administration of 60 or 
250 mg kg - i, respectively, to subjects with u-l anti- 
trypsin deficiency was found to augment serum a-l 
antitrypsin levels and activity to above threshold 
levels (52-55). In addition, analysis of broncho- 
alveolar lavage fluid collected at regular intervals 
showed that the inhibitor reached the epithelial lining 
fluid significantly above the level and activity 
recorded prior to treatment. However, although 
the protein reaches the desired site of action, the 
intravenous route requires high doses. 
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An alternative route is via inhalation. Both 
Prolastin and recombinant human u-l antitrypsin 
have been administered as aerosols (5657). Deliv- 
ery of up to 200 mg of the recombinant protein 
to a-1-antitrypsin-deficient subjects significantly 
enhanced the antineutrophil elastase capacity recov- 
ered (57). Thus, 4 and 24 h after 200 mg of aero- 
solized protein, elastase inhibitory capacity was 
increased by 40- and 5-fold, respectively, over base- 
line levels. Although recombinant protein is not 
glycosylated and may, therefore, be rapidly cleared 
when given intravenously, this may be an advantage 
when given via inhalation since it may facilitate 
passage into the interstitium. It is suggested that 
100 mg twice daily would provide adequate protec- 
tion against neutrophil elastase, although more 
studies need to be carried out using this route of 
delivery (58). 
An alternative approach to a-l antitrypsin therapy 
is to counteract excessive neutrophil elastase activity 
in the lung by preventing pulmonary neutrophil 
accumulation (59). Circulating neutrophils from 
patients with emphysema have significantly more 
formyl-peptide receptors (transmembrane proteins 
coupled to G proteins that trigger neutrophil chemo- 
taxis and/or degranulation) compared with control 
subjects, smokers without emphysema, and patients 
with other diseases (e.g. bronchiectasis). Smoking 
may also be a contributory factor to increased recep- 
tor number. It was suggested that an enhanced 
neutrophil chemotactic response may contribute to 
the susceptibility of patients with emphysema but 
normal u-l antitrypsin levels. Similarly, neutro- 
phils from patients with COPD show enhanced 
extracellular proteolytic capacity (60). 
Questions from the floor included whether there 
was a possibility of a-l antitrypsin gene therapy. The 
gene has been transfected into epithelial cells in vitro 
and into rat lung via inhalation (61). However, many 
of the problems associated with CF gene therapy via 
inhalation apply to u-l antitrypsin. Other sites for 
gene transfection include the endothelium and liver. 
An alternative is liver transplantation. Whichever 
method, the therapy would have to address the 
problem of accessibility of the protein to lung tissue 
to reach threshold levels and the feasibility, with gene 
therapy, of repeated treatment. Returning to Prolas- 
tin therapy, we were reminded that the European 
trials were in their third year. Dr Duncan Hutchison 
informed us that the results of the 3 yr stage would be 
available soon. It was suggested that if regular treat- 
ment with Prolastin did not work over this period of 
time, it would be questionable whether it would be 
worth continuing. 
Future Trends in Asthma Therapy 
Asthma affects over 6% of the population and, 
despite being considered a ‘treatable’ condition, the 
incidence of asthma is not on the wane, and it may 
even be on the increase. Thus, despite the current 
availability of a number of classes of drug for treat- 
ment of asthma, there is clearly a need for improved 
therapy. Future trends in asthma therapy was 
addressed by Professor Peter Barnes (National Heart 
& Lung Institute, London) who remarked, somewhat 
wryly, that development of new treatments for 
asthma would have been a better title for his presen- 
tation because the future trends in asthma therapy 
were the continued use of inhaled &agonists and 
glucocorticosteroids. Theophylline, particularly at 
low doses (62), and anti-cholinergics provide possible 
alternative therapy. Consequently, at the simplest 
level, future developments would be first line treat- 
ment with steroids (63) and avoidance of regular use 
of a-agonists (64), introduction of long-acting 
P-agonists, development of better inhalation devices, 
and improvements in patient self-management. New 
classes of drugs could be developed and old drugs 
could be improved in terms of duration of action, 
selectivity and incidence of side-effects, either based 
upon scientific research or due to serendipity. 
Perhaps new bronchodilators could be developed. 
In addition to B-agonists, vasoactive intestinal pep- 
tide (VIP) and prostaglandin (PG) E, are bronchodi- 
lators in experimental animals. Vasoactive intestinal 
peptide currently has little therapeutic potential in 
humans due to degradation by airway peptidases, 
whereas PGE, may have more potential (65). Devel- 
opment of therapies which target the intracellular 
signal transduction mechanisms mediating broncho- 
dilation is a more direct approach which could 
overcome these problems. Interaction of the 
bronchodilator compound with its specific cell- 
surface receptor activates adenylyl cyclase via a 
pertussis-toxin-sensitive guanine nucleotide binding 
protein (G-protein; G,) with consequent conversion 
of adenosine triphosphate (ATP) to cyclic adenosine 
monophosphate (CAMP) which mediates airway 
smooth muscle relaxation (Fig. 3). However, not all 
of the smooth muscle relaxant properties of broncho- 
dilators, in particular P-agonists, can be accounted 
for by accumulation of intracellular CAMP (66) and 
may be due to opening of potassium (K+) channels in 
the cell membrane (Fig. 3). Thus, drugs which open 
K’ channels may be novel bronchodilators (67). The 
first effective K’ channel opener to be developed was 
cromakalim, which opened ATP-sensitive K’ (K,,,) 
channels, and was shown to be a smooth muscle 
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Fig, 3 Bronchodilator mechanisms. Interaction of ligand (e.g. P-agonist, prostaglandin E, or vasoactive intestinal peptide) 
with G-protein-coupled receptor (R) on plasma membrane of airway smooth muscle cells activates adenylyl cyclase (AC) to 
form 3’5’ cyclic adenosine monophosphate (CAMP), which in turn activates protein kinase A (PKA). PKA has a number of 
effects which may lead to smooth muscle relaxation (PI, phosphoinositide). Development of drugs which open large 
conductance calcium-activated potassium channels (BK,,), or reduce CAMP degradation by inhibiting phosphodiesterase 
enzymes (PDE) are options for novel bronchodilator therapy. 
relaxant in vitro and in vivo in experimental animals. 
However, it was not particularly effective as a bron- 
chodilator when given orally in humans and did not 
inhibit histamine- or methacholine-induced bron- 
choconstriction. Headache and postural hypotension 
were notable side-effects due to the vasodilatation 
associated with opening of KATr, channels. Inhala- 
tion of the drug in an attempt to avoid the systemic 
side-effects proved ineffective as postural hypoten- 
sion developed more rapidly than after oral adminis- 
tration. Thus, development of ‘airway-specific’ K’ 
channel openers which do not affect the vasculature 
is required. These may be found in drugs which open 
the large conductance calcium (Ca’+)-activated K’ 
(maxi-K or BK,-,) channel (68). One of these, 
NS1619, which has been developed from a Guyanan 
asthma folk remedy, merits further study (69). 
Development of selective receptor antagonists or 
antibodies to putative mediators of asthma is another 
approach. New mediators are proposed regularly, 
and currently include cytokines and adhesion mol- 
ecules. However, because so many mediators could 
be involved in asthma, it may prove difficult to 
develop drugs with a large clinical effect (70). In the 
majority of cases these mediator antagonist drugs, 
although proving useful in the elucidation of mech- 
anisms, do not inhibit asthma symptoms in humans. 
The classic example is platelet activating factor 
(PAF) which received considerable interest as a 
mediator of asthma, but the lack of effect of PAF 
antagonists in reducing corticosteroid requirement by 
asthmatics questions this view (71,72). Exceptions are 
antagonists of cysteinyl leukotrienes (LT) and inhibi- 
tors of S-lipoxygenase activity, both of which have 
been shown to have clinical benefit in asthmatic 
patients (73). In particular, 6 weeks oral administra- 
tion of Accolate (ICI 204,219), an LTD, receptor 
antagonist, is safe and improves subjective and objec- 
tive measures of asthma in moderately ill asthmatics 
(74), although not as effectively as corticosteroids, 
and is the first effective new anti-asthma drug in 
25 yr. 
Inhaled glucocorticosteroids are first-line therapy 
for chronic asthma, but there are concerns about 
safety, particularly when high doses are used for 
prolonged periods (75). Perhaps there could be 
improvements in inhaled corticosteroids, in particu- 
lar to enhance the topical:systemic effect ratio and 
reduce adverse side-effects (76). Areas for improve- 
ment include increased topical potency, decreased 
systemic absorption, or increased local metabolism. 
The latter have been termed ‘hit and run’ or ‘soft’ 
steroids in which the target cell alone is affected. 
Unfortunately, these steroids do not appear to 
work in asthma because they are metabolized too 
effectively, which limits their duration at the site of 
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action. Increasing first pass metabolism is unlikely 
to markedly reduce systemic absorption. The vast 
majority of systemic availability is via lung-airway 
absorption, and only one-quarter of that has a 
hepatic first pass. Thus, increasing hepatic inactiva- 
tion will only marginally improve systemic tolerance. 
Addition of possibilities for extra-hepatic inactiva- 
tion to the drug molecule may be a fruitful approach. 
Other options are prolonged deposition (‘depot’) 
steroids, cell targeting using liposomes, and ‘non- 
steroidal’ steroids. However, steroids only work 
because they interact with the glucocorticoid receptor 
(77) and current interest is on drugs which act 
similarly. 
Theophylline inhibits phosphodiesterase (PDE), 
which in turn leads to an increase in intracellular 
CAMP and causes airway smooth muscle relaxation 
and bronchodilation. However, there are numerous 
PDE isoforms and theophylline is a very weak and 
non-selective PDE inhibitor. There are at least seven 
‘families’ of PDE, comprising more than 20 separate 
isoenzymes, many with selective inhibitors (78). PDE 
IV appears to be the isoenzyme of greatest relevance 
to the airways being not only a bronchodilator but 
also having inhibitory effects on a variety of inflam- 
matory cells including mast cells, eosinophils, alveo- 
lar macrophages and T lymphocytes. PDE IV 
inhibitors are, therefore, of great clinical interest. 
Early studies appear promising although the pre- 
dominant side-effects of nausea and vomiting are, at 
present, discouraging. Longer treatment with lower, 
non-emetic doses may avoid these problems. Never- 
theless, the concept of drugs, such as the PDE 
inhibitors, with combined bronchodilator and anti- 
inflammatory activity is exciting. Even if the PDE 
inhibitors do not fulfill their early promise, the poten- 
tial for rational development of non-steroidal drugs 
with multiple beneficial activity has been proven. The 
ultimate aim for asthma therapy is to develop drugs 
which are more specific for asthma, lack adverse 
side-effects and are orally active to improve patient 
compliance. 
Novel Inhalation Devices 
Effective drug delivery to the lung remains a prob- 
lem: only 10% of the dose emitted from a pressurized 
metered-dose inhaler (MDI) reaches the distal air- 
ways. As a consequence, it would seem reasonable to 
link development of any new inhaled medication to 
improvements in delivery systems. The poor inhaler 
technique of a remarkable number of patients (at 
least one-half of adults using MDIs, and worse for 
children) (79) has prompted the pharmaceutical and 
biotechnological industries to improve the design of 
inhaler devices. Other factors driving development of 
new inhaled medications are the pressures to replace 
the chlorofluorocarbon (CFC) propellants in MDIs 
with non-CFC alternatives, and the expiry of patent 
of a number of inhaled medications which has 
allowed new companies to produce generic alterna- 
tives (80). The effectiveness of new inhaler devices 
should be at least comparable to currently available 
devices. They should also be small in size, light- 
weight, multiple-dose, simple to use correctly, accept- 
able to patients, inexpensive, non-ozone depleting, 
applicable to a range of drugs and dosages, and 
provide a reliable, accurate and reproducible dose. 
As Dr Steve Newman (Pharmaceutical Profiles, 
Nottingham) demonstrated, many new devices are in 
development although each has its own advantages 
and disadvantages depending upon the clinical 
setting. Currently, delivery systems for inhaled medi- 
cations fall into three broad categories, namely MDI, 
dry powder inhaler (DPI) and nebulizer (81). 
Current wisdom is that the DPI is a better delivery 
device than the MD1 because it retains many of the 
advantages (speed of use, compactness and port- 
ability) of the MD1 but with fewer limitations 
(dependance on patient coordination and propellant 
technology). Nevertheless, there is continued interest 
in the MD1 and new non-CFC aerosol formulations 
are being explored, in particular the hydrofluoro- 
alkanes (HFAs) 134a and HFA 227. These new 
formulations bring their own technical problems, 
related to optimization of spray characteristics and 
vapour pressure, and will require extensive toxicity 
testing. However, it seems likely that non-CFC-based 
MDIs will become commercially available within the 
next 2-3 yr. Breath-actuated MDIs, such as the 
Autohaler and the newer Gentlehaler (82), may prove 
a fruitful line of development for the patient who 
consistently cannot coordinate device activation 
with inhalation. 
At least 15 new multidose DPIs are currently in 
development, although they are generally variations 
upon existing devices. Many are so new that they are 
only just becoming publicised at conferences or in the 
patent literature. The new DPIs include those which 
meter bulk powder into a dosing unit (based upon the 
Turbohaler design), and devices in which individual 
doses have been predispensed, for example into 
‘blister’ packs (based upon the Diskhaler design). 
Novel DPIs may be further subdivided into ‘passive’ 
systems, in which the powder is metered or dispensed 
in response to inhalation by the patient, and 
‘active’ systems which use an external power source, 
for example a small compressed air supply or a 
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battery-operated electric motor. The design of these 
new devices should protect the drug powder from 
moisture and they should operate at an appropriate 
flow rate for the patient. 
Nebulizer design is also being reassessed, and may 
threaten the pressurized MDI. Current conventional 
nebulizer therapy involves use of bulky apparatus to 
aerosolize a few millilitres of drug solution over 
10-15 min. However, the next few years may witness 
the development of miniaturized and portable neb- 
ulizers which deliver a small spray bolus in under a 
second by utilizing sonification and highly com- 
pressed gas to discharge the spray. Perfection of these 
systems would constitute a genuine alternative to 
the MDI. 
From the above, it may be seen that most new 
devices are variations on an existing theme. However, 
a number of totally new designs are now being 
described, including hand-actuated, propellant-free 
spray devices (83,84), and a manually-operated 
device for dispensing a predetermined amount of 
powdered drug, the Dynamic Powder Dispenser (85). 
It will be interesting over the next few years to see an 
increasingly wide range of delivery systems become 
available for inhaled medications. How the practi- 
tioner will determine which to use will be the subject 
of even greater interest. 
Possibilities for Treatment of Pulmonary Fibrosis 
Lung fibrosis is perhaps one of the most difficult 
conditions to treat and was addressed in breadth, but 
with brevity, by Dr Ron DuBois. Fibrosis is the result 
of early injury and it is critical to treat as soon as 
possible since it reaches a stage that is impossible to 
reverse. The aim is either to prevent fibrogenesis or to 
prevent its progress, depending upon the stage the 
disease has reached. It seems likely that there is a 
predisposition for some individuals to develop fibro- 
sis although this area of research is in its infancy. 
Studies on predisposition have included investigation 
of key cytokines, cytokine receptors, HLA and MHC 
molecules. Analysis of HLA haplotypes suggests that 
there is a relationship between specific haplotypes 
and development of fibrosis after injury, since an 
incidence of 45% was observed in those with pulmo- 
nary fibrosis compared with only 6% in others with- 
out lung fibrosis. Significantly, the relevant HLA 
haplotype appears to be linked to the genes that are 
involved with pulmonary fibrosis, on chromosome 6. 
The problem of therapy for pulmonary fibrosis is 
the multitude of possible mechanisms underlying the 
disease process. The injury that leads to fibrosis 
triggers an influx of inflammatory cells including 
neutrophils, eosinophils and macrophages that pro- 
duce a host of mediators which may promote fibro- 
genesis. Resident cells may also be activated to 
release similarly active molecules, either by mediators 
released by inflammatory cells or by the injurious 
agent. Cytokines that promote growth or cell differ- 
entiation have received much attention. It is believed 
that once these cytokines are released, autocrine and 
paracrine reactions occur that exacerbate the situ- 
ation. For example, resident cells change phenotype 
and differentiate, and connective tissue gene expres- 
sion and other molecules important in matrix 
metabolism and deposition (such as matrix metallo- 
proteinases) are differentially expressed in favour of 
excessive matrix deposition. 
Although the fibroblast may appear to be the 
obvious first target in the fibrogenic process both the 
endothelium and epithelium, which appear normal 
by light microscopy, are abnormal at the electron- 
microscopic level. Tumour necrosis factor a (TNFa) 
is believed to be one of the first cytokines to increase 
in lung injury; it is known to stimulate endothelial 
cell adhesion molecule synthesis, and hence the prob- 
ability of leucocyte adhesion and migration into the 
interstitium. Such processes may be important during 
the early stages of injury, stimulating inflammatory 
cell influx and release of mediators that lead to 
fibrosis. 
Endothelin 1 is a cytokine that is produced by 
endothelial, fibroblastic and epithelial cells. It is 
elevated in bronchoalveolar lavage fluid obtained 
from patients with systemic sclerosis (86). The bron- 
choalveolar lavage fluid is mitogenic, stimulating 
fibroblast proliferation in vitro; this mitogenic activ,- 
ity could be inhibited by up to 40% by neutralizing 
antibodies and synthetic endothelin 1 receptor lig- 
ands, suggesting that endothelin 1 is at least one of 
the cytokines involved in the pulmonary fibrosis seen 
in these subjects (86). Insulin-like growth factor may 
account for some of the remaining mitogenic activity 
(87). Another source of growth-promoting activity 
might be soluble factors generated after clot forma- 
tion (88). Thrombin, fibrinopeptides A and B and 
other higher molecular weight cleavage products gen- 
erated during clot formation have mitogenic activity 
when applied to fibroblasts. 
Transforming growth factor /3 (TGFP) invariably 
promotes connective tissue production by fibroblasts 
(89) but it can also promote fibroblast proliferation, 
depending on the stage of growth of the fibroblasts. 
At the same time, enzymes that break down connec- 
tive tissue such as collagenase are down-regulated by 
TGFD. Its mitogenicity may also depend upon the 
presence of other growth factors (e.g. platelet derived 
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growth factor) and, in addition, TGFP promotes 
selection of a more aggressive fibroblast phenotype 
that is profibrogenic (90). In situ hybridization and 
immunolocalization studies in animal models and 
human tissue (89-91) have highlighted the likely role 
of the monocyte/macrophage as a rich source of 
TGFB during pulmonary fibrosis; in addition, the 
epithelium of fibrotic lung tissue expresses elevated 
TGFB levels. Furthermore, TGF/3 has been localized 
extracellularly to areas of active fibrosis in tissue 
from subjects with idiopathic fibrosis and cryptogenic 
fibrosing alveolitis, suggesting that matrix-associated 
TGFP may be one mechanism of induction of per- 
sistent expression of connective tissue genes by lung 
fibroblasts (89,91). 
One of the earliest changes in the lung is an 
increase in IL-8 a chemokine that is a potent 
neutrophil chemoattractant, in bronchoalveolar 
lavage fluid obtained from patients at risk of devel- 
oping adult respiratory distress syndrome (ARDS) 
(92). TNFa, circulating levels of which are also 
increased in ARDS, up-regulates IL-8 and probably 
precedes the IL-8 response in the lung. Broncho- 
alveolar lavage levels of IL-8 are positively correlated 
with neutrophil number. This accords with the con- 
sistent finding of elevated neutrophil numbers in 
fibrosing lung diseases. 
TNFa has attracted considerable attention as an 
important mediator of the early response to lung 
injury, since plasma levels increase rapidly following 
the initial insult (93). TNFa is increased in lung 
lavage from patients with ARDS (94) and in mono- 
cytes and epithelial cells in biopsies from patients 
with idiopathic pulmonary fibrosis (95). Animal 
models have confirmed the significance of TNFa in 
fibrotic lung disease. Intratracheal instillation of a 
single dose of silica or bleomycin in mice causes 
fibrosis that involves increased TNFa expression and 
levels; treatment (intraperitoneal or i.v. infusion) of 
these animals with TNFa antibodies or TNF receptor 
antagonists prevents development of fibrosis and 
reduces collagen synthesis (96,97), illustrating a 
possible fundamental role for TNFa in pulmonary 
fibrosis. TNFa is synthesized as an inactive, latent 
precursor of 26 kDa and needs to be processed to the 
17 kDa molecule for biological reactivity. Proteolytic 
cleavage by metalloproteinases has been identified as 
a major mechanism of TNF activation which can be 
controlled by specific inhibition of matrix metallo- 
proteinase activity (98,99), an important finding in 
terms of therapeutic intervention. 
It is clear that the mechanisms underlying pul- 
monary fibrosis are complex and involve inter- 
actions between numerous mediators and possibly 
predisposition of the individuals affected. Without a 
grasp of the genes involved, therapy involving gene 
transfer is not feasible. However, there are some key 
mediators which modulate different stages of the 
disease process, although it is debatable whether a 
single mediator can be pinpointed for targeted 
therapy. Blocking TNFa synthesis, secretion or reac- 
tivity may be useful. Similarly, treatment with anti- 
bodies to TGFP has been shown to partially 
ameliorate bleomycin-induced-fibrosis in mice (100). 
A cautionary note concerning targeting of single 
cytokines to treat lung fibrosis has been expressed by 
Laurent et al. (101). They remind us not only of the 
multitude of alternative profibrotic mediators and 
mechanisms that co-exist with each other but also of 
the importance of the mode and timing of specific 
therapy (i.e. the disease process may be too far 
advanced). Possible therapeutic alternatives include 
use of soluble receptor antagonists, receptor ligand 
analogues and monoclonal antibodies which are cur- 
rently being used successfully to treat rheumatoid 
arthritis. Although our understanding of the mecha- 
nisms of pulmonary fibrosis has progressed rapidly 
during the last decade, it appears that we are still a 
long way from routine treatment. 
Professor John Widdicombe was interested to know 
how, in the event of developing a suitable drug, it 
could be delivered to the relevant site of action. Since 
the interstitium is affected, the problem is one of 
delivery to the periphery and to the appropriate cells. 
Clearly, monocytes and epithelial cells are a source 
of many of the profibrotic cytokines, while the 
‘aggressive’ fibroblast might need targeting to down- 
regulate matrix production. Obviously, inhalation of 
appropriately formulated compounds would be the 
least invasive method but might be unsuccessful in 
advanced disease. Systemic delivery might be better 
in these subjects, but would depend on the nature of 
the compound used. Ideally, treatment should take 
place as early as possible in the disease process to 
optimize drug delivery and outcome. 
Medical Aspects of Lung and Heart-Lung 
Transplantation 
The final presentation of the day on medical 
aspects of lung transplantation by Dr Tim 
Higenbottam (Papworth Hospital, Cambridge) 
reminded us that drug therapy was not the only 
option for treatment of lung disease. Lung and, more 
particularly, heart-lung transplantation has proved 
highly successful in the treatment of many hundreds 
of patients with various end-stage lung diseases, 
including pulmonary vascular disease, cardiac disease 
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associated with pulmonary hypertension, pulmonary 
fibrosis, emphysema and cystic fibrosis (102-104). 
Heart-lung transplantation has even been successful 
in systemic lupus erythematosus (SLE) (105). The 
major clinical manifestation leading to increased 
morbidity and limited survival following transplanta- 
tion is chronic rejection characterized by develop- 
ment of bronchiolitis obliterans, an unexplained and 
usually fatal condition which remains unresponsive 
to treatment (106). Bronchiolitis obliterans invariably 
appears 6-l 8 months following transplantation, 
starting as inflammation of the terminal and respira- 
tory bronchioles with infiltration of lymphocytes and 
plasma cells (107). Ulcerated and sloughed-off epithe- 
lial debris occupies the airway lumen. Subsequently, 
fibroblast activity in the area lays down concentric 
sheets of collagen so that the airways become 
occluded with ‘onion-like’ plugs of collagen. The 
bronchioles become rigid leading to bronchiectatsis 
and recurrent infection. Deterioration is rapid, going 
from near normality to end-stage disease or retrans- 
plantation within a few months (108,109). The inci- 
dence of bronchiolitis varies between centres, but 
current estimates are that there is an overall incidence 
of 40% in those patients who survive for more than 
6 months following transplantation. Distressingly, 
the incidence of bronchiolitis obliterans is greater in 
transplanted children (110). The mechanisms under- 
lying the pathogenesis of bronchiolitis obliterans 
remain ill-defined. Neither chronic rejection (i.e. an 
immunologic mechanism) nor infection, in particular 
due to cytomegalovirus, appear to account fully for 
the development of the condition (11 l), although a 
combination of the two is favoured by many 
researchers. Ischaemic damage, occuring either at the 
time of transplant or as a result of lack of a bronchial 
circulation, is another possibility. Future strategies to 
reduce or prevent bronchiolitis obliterans include 
development of better immunosuppressive agents 
(112), better control or prevention of cytomegalo- 
virus infection, and exploration of techniques to 
improve arterial circulation to the transplanted 
lung. Direct revascularization may be achieved using 
the internal mammary artery or, less successfully, 
saphenous vein or a reconstructed donor aortic 
conduit (102). 
Heart-lung transplantation is a comparatively new 
surgical procedure compared, for example, with 
kidney transplantation. Consequently, although less 
basic immunology is known about heart-lung trans- 
plantation, much can be learned from other trans- 
plantation research. For example, donor organs such 
as the liver contain immunologically significant 
‘passenger leucocytes’ which are passed to the 
recipient. Small pockets of these donor cells, mainly 
dendritic cells which are normally associated with 
tolerogenicity, have been found ubiquitously distrib- 
uted in recipients up to 30 years following transplan- 
tation (113,114). This phenomenon is termed 
‘microchimerism’. The implication is that if the acute 
phase of rejection is controlled by modern immuno- 
suppression regimes, the chimeric cells are able to 
modify the immune response and a natural tolerance 
to the graft can be induced, no matter what the organ 
transplanted. The extensive population of leucocytes 
in the lung indicates the importance of investigation 
of microchimerism and graft acceptance in lung and 
heart-lung transplantation. 
As well as being an option for therapy of severe 
respiratory disorders, lung and heart-lung transplan- 
tation offer the unique opportunity to study the 
functioning of the lung after extrinsic denervation. 
For example, is there re-innervation of the trans- 
planted lung? Examination of rejected transplanted 
lungs removed at retransplantation showed that there 
is some persistence of pulmonary nerves and of 
neuropeptide synthesis after heart-lung transplanta- 
tion (115). More interestingly, there was evidence of a 
possible change in intrinsic parasympathetic nerves 
to a sympathetic phenotype. Another question con- 
cerns whether or not transplant patients develop 
airway hyper-responsiveness. For heart-lung or 
double lung transplant patients with normal lung 
histology, it appears they do not (116). Asthma is 
characterized by airway hyper-responsiveness (117) 
and transplantation may give us insights into its 
pathogenesis. For example, normal subjects show 
little airway narrowing in response to inhaled 
capsaicin (118). In contrast, heart-lung transplant 
patients can show a bronchodilation, whilst capsaicin 
can cause bronchoconstriction in asthmatic patients. 
Further studies extending these observations may 
lead to a greater understanding of the neural control 
of the airways than could be achieved before the 
availability of transplanted subjects. This aspect is 
demonstrated in a fascinating study (119). Trans- 
planting normal lungs into two asthmatic patients, 
and transplanting mild asthmatic/atopic lungs into 
non-asthmatic patients, showed that the previously 
asthmatic patients lost their asthma symptoms whilst 
the non-asthmatic patients developed asthma. 
Although clearly requiring confirmation in a larger 
number of patients, these observations support the 
concept of asthma as a ‘local’ disease. 
Conclusions 
The BALR symposium amply demonstrated the 
breadth and depth of current research into lung 
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disease and gave hope for treatment for patients with 
severe respiratory disorders. What of future develop- 
ments in the therapy of lung disease? Gene transfer, 
although not quite out of its infancy, is showing 
potential and gene therapy for patients with CF and 
u-l antitrypsin deficiency is becoming a realistic goal. 
It will be fascinating to observe the development of 
gene therapy and to see if it becomes applicable to 
other lung disorders, for example asthma or other 
bronchial diseases associated with atopy for which 
there is evidence of genetic inheritance. In the mean- 
time, and also for those diseases not obviously gov- 
erned by inheritance, the new technologies being 
harnessed by the pharmaceutical and biotechnologi- 
cal industries coupled with research-based rational 
design should lead to development of more effective 
and safer drugs. The possibilities for effective therapy 
for a number of lung diseases are increasing rapidly. 
Experience with false dawns in therapy advises 
caution and suggests that few of these possibilities 
will be turned into clinical practice before the start of 
the next millenium. We would be delighted to be 
proved wrong. 
Acknowledgements 
The authors thank Dr Noel Sell for his helpful 
comments on the manuscript. The BALR wishes to 
thank Allen & Hanburys, Fisons Pharmaceuticals 
and Rhone Poulenc Rorer for their sponsorship. 
References 
1. DiMasi JA. Risks, regulation, and rewards in new drug 
development in the United States. Regulatory Toxic07 
Pharmacol 1994; 19: 228-235. 
2. DiMasi JA, Seibring MA, Lasagna L. New drug devel- 
opment in the United States from 1963 to 1992. C/in 
Pharmacol Ther 1994; 55: 611-622. 
3. Grabowski H, Vernon J. A new look at the returns and 
risks to pharmaceutical R&D. Management Sci 1990; 
36: 804 821. 
4. Bohacek RS, McMartin C. Exploring the universe of 
molecules for new drugs. Nature Med 1995; 1: 177-178. 
5. Duchin JS, Koster FT, Peters CJ et al. Hantavirus 
syndrome: a clinical description of 17 patients with 
newly recognised disease. New Engl J Med 1994; 330: 
949-955. 
6. Levv H, Simpson SO. Hantavirus pulmonary syndrome. 
Am-J Respir‘Crit C&e Med 1994-149: 171d-1713. 
7. Han LY. Wilson R. Slater S et al. In vitro and in vivo 
effects of ribavirin on human respiratory epithelium. 
Thorax 1990; 45: 100-104. 
8. Snell NJC. Delivery of antiviral medication via a small 
particle aerosol generator (SPAG). J Aerosol Med 1991; 
4 CSUPP~ 1): 16. 
9. Caps& LJ, Jones KL, Snell NJC. Safety and tolerance 
of nebulised ribavirin in clinical usage. Acta Ther 1992; 
18: 133-147. 
10. 
11 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
Higgins PG, Barrow GI, Tyrrell DAJ, Snell NJC, Jones 
K, Jolley WB. A study of the immunomodulatory 
compound 7-thia-8-oxoguanosine in coronavirus 229E 
infections in human volunteers. Antiviral Chem 
Chemother 1991; 2: 61-64. 
Proud D, Gwalney JM Jr, Hendley JO, Dinarello CA, 
Gillis S, Schleimer RP. Increased levels of interleukin-1 
are detected in nasal secretions of volunteers during 
experimental rhinovirus colds. J Infect Dis 1994; 169: 
1007-1013. 
Hendley JO, Abbott RD, Beasley PP, Gwaltney JM Jr. 
Effect of inhalation of hot humidified air on experimen- 
tal rhinovirus infection. J Am Med Assoc 1994; 271: 
1112-1113. 
Woods et al. 4-guanidino NeuSAc 2en (GR 121167). 
Antimicrob Azents Chemother 1993: 37: 1473. 
Rieder HL. Drug-resistant tuberculosis: issues in epi- 
demiology and challenges for public health. Tubercle 
Lung Dis 1993; 75: 321-323. 
Iseman MD. Treatment of multidrug-resistant tubercu- 
losis New Engl J Med 1993; 329: 784791. 
Iseman MD. Evolution of drug-resistant tuberculosis: 
A tale of two species. Proc Nat1 Acad Sci USA 1994; 91: 
2428-2429. 
Walker DA, Taylor IK, Mitchell DM, Shaw RJ. Com- 
parison of polymerase chain reaction amplification of 
two mycobacterial DNA sequences, IS6110 and the 
65kDa antigen gene, in the diagnosis of tuberculosis. 
Thorax 1992; 47: 69&694. 
Goyal M, Ormerod LP, Shaw RJ. Epidemiology of an 
outbreak of drug-resistant tuberculosis in the UK using 
restriction fragment length polymorphism. Clin Sci 
1994; 86: 749-751. 
Stanford JL, Grange JM. The promise of immuno- 
therapy for tuberculosis. Respir Med 1994; 88: 3-7. 
Hodson ME. Cystic fibrosis: the disease. Monaldi Arch 
Chest Dis1993; 48: 647-652. 
Riordan JR. The cystic fibrosis transmembrane 
conductance regulator. Annu Rev Physiol 1993; 55: 
6099630. 
Alton E, Geddes D. Gene therapy for cystic fibrosis: a 
clinical perspective. Gene Therapy 1995; 2: 1-8. 
Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current 
survival and population estimate to the year 2000. 
Thorax 1991; 46: 881-885. 
Knowles MR, Church NL, Waltner WE et al. A pilot 
study of aerosolised amiloride for the treatment of iung 
disease in cystic fibrosis. New Enal J Med 1990: 322: 
1189-1194. _ 
Graham A, Hasani A, Alton EWFW et al. No added 
benefit from nebuhzed amiloride in patients with cystic 
fibrosis. Ear Respir J 1993; 6: 1243-1248. 
Engelhardt JF, Yankaskas JR, Ernst SA et al. Sub- 
mucosal glands are the predominant site of CFTR 
expression in the human bronchus. Nature Genetics 
1992; 2: 240-248. 
Engelhardt JF, Zepeda M, Cohn JA, Yankaskas JR, 
Wilson JM. Expression of the cystic fibrosis gene in 
adult human lung. J Clin Investl994; 93: 737-749. 
Trapnell BC, Chu C-S, Paakko PK et al. Expression of 
the cystic fibrosis transmembrane conductance regu- 
lator gene in the respiratory tract of normal individuals 
and individuals with cystic fibrosis. Proc Nat1 Acad Sci 
USA 1991; 88: 6565- 6569. 
BALR Symposium 21 
Laurel1 C-B, Eriksson S. The electrophoretic alpha,- 
globulin pattern of serum in alpha,-antitrypsin 
deficiencv. Stand J Clin Lab Invest 1963: 15: 
132-140: 
29. Crawford I, Maloney PC, Zeitlin PL et al. Immuno- 46. 
cytochemical localisation of the cystic fibrosis gene 
product CFTR. Proc Nat1 Acad Sci USA 1991; 88: 
9262-9266. 
30. 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
39. 
40. 
41. 
42. 
43. 
44. 
45. 
Crystal R. The gene as the drug. Nature Med 1995; 1: 
15-17. 
Zabner J, Couture LA, Gregory RJ, Graham SM, 
Smith AE, Welsh MJ. Adenovirus-mediated gene trans- 
fer transiently corrects the chloride transport defect 
in nasal epithelia with cystic fibrosis. Cell 1993; 75: 
207-2 16. 
Caplen NJ, Alton EWFW, Middleton PG et al. 
Liposome-mediated CFTR gene transfer to the nasal 
enithelium of patients with cvstic fibrosis. Nature Med 
1995; 1: 3948. 
Zhu N, Liggitt D, Debs R. Systemic gene expression 
after intravenous DNA delivery into adult mice. Science 
1993; 261: 2099211. 
Dodge JA. Gene therapy for cystic fibrosis. Nature Med 
1995; 3: 182. 
Aitken ML. Clinical trials of recombinant human 
DNase in cystic fibrosis patients, Monaldi Arch Chest 
Dis 1993; 48: 6533656. 
Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker 
CL. Recombinant human DNase I reduces the viscosity 
of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 
87: 91889192. 
Green JD. Pharmacological-toxicological expert report: 
Pulmozyme (rhDNase). Human Exp Toxicol 1994; 13: 
St-S42. 
Aitken ML, Burke W, McDonald G, Shak S, 
Montgomery AB, Smith AL. Recombinant human 
DNase inhalation in normal subjects and patients with 
cvstic fibrosis. A vhase I study. J Am Med Assoc 1992; 
2b7: 194771951. . 
Hubbard RC, McElvany NG, Birrer P et al. A prelimi- 
nary study of aerosolised recombinant human deoxy- 
ribonuclease I in the treatment of cystic fibrosis. New 
Engl J Med 1992; 326: 812-815. 
Ranashinha C, Assoufi B, Shak S et al. Efficacy and 
safety of short-term administration of aerosolised 
recombinant human DNase 1 in adults with stable stage 
cystic fibrosis. Lancet 1993; 342: 199-202. 
Ramsey BW, Astley SJ, Aitken MI et al. Efficacy and 
safety of short-term administration of aerosolized 
recombinant human deoxyribonuclease in patients with 
cystic fibrosis. Am Rev Respir Dis 1993; 148: 141-151. 
Fuchs HJ, Borowitz DS, Christiansen DH et al. Effect 
of aerosolized recombinant human DNase on exacer- 
bations of respiratory symptoms and on pulmonary 
function in patients with cystic fibrosis. New Engl J Med 
1994; 331: 637-642. 
Wilmott R. A phase II, double-blind, multicenter study 
of the safety and efficacy of aerosolised recombinant 
human DNase I (rhDNase) in hospital patients with CF 
experiencing acute pulmonary exacerbations. Pediatric 
Pulmonol; (suppl 9): 154. 
Shah PL, Scott SF, Hodson ME. Report on multicentre 
study using aerosolised recombinant human DNase I in 
patients with severe pulmonary disease. Pediatric 
Pulmonol 1993; (suppl 9): 1577158. 
Shah PL, Scott SF, Hodson ME. Lobar atelectasis in 
cystic fibrosis and treatment with recombinant human 
DNase I. Respir Med 1994; 88: 313-315. 
47. 
48. 
49. 
50. 
51. 
52. 
53. 
54. 
55. 
56. 
57. 
58. 
59. 
60. 
61. 
Beatty K, Bieth .I, Travis J. Kinetics of association of 
serine proteinases with native and oxidised alpha-l- 
proteinase inhibitor and alpha-1-antichymotrypsin. 
J Biol Chem 1980; 255: 3931-3934. 
Kalsheker NA, Morgan K. Regulation of the 
a,-antitrypsin gene and a disease-associated mutation in 
a related enhancer sequence. Am J Respir Crit Care 
Med 1994; 150: 183-189. 
Carrel1 RW, Jeppsson J-O, Laurel1 C-B, Brennan SO, 
Owen MC. Vaughan L. Boswell DR. Structure and 
variation of human a,-antitrypsin. Nature 1982; 298: 
329-334. 
Lomas DA, Evans DL, Finch JT, Carrel1 RW. The 
mechanism of Z a,-antitrypsin accumulation in the 
liver. Nature 1992; 357: 605-607. 
Damiano VV, Tsang A, Kucich U, Abrams WR, 
Rosenbloom J. Kimbel P. Fallahneiad M. Weinbaum 
G. Immunolocalisation of elastase in human emphyse- 
matous lungs, J Clin Invest 1986; 78: 482-493. 
Wewers MD, Casolaro MA, Sellers SE et al. Replace- 
ment therapy for alpha,-antitrypsin deficiency associ- 
ated with emphysema. N Engl J Med 1987; 316: 
1055-1062. 
Hubbard RC, Crystal RG. Alpha-1-antitrypsin aug- 
mentation therapy for alpha-1-antitrypsin deficiency. 
Am J Med 1988; 84 (6A):. 52-62. 
Hubbard RC, Sellers S, Czerski D, Stephens L, Crystal 
RG. Biochemical efficacy and safety of monthly aug- 
mentation therapy for a,-antitrypsin deficiency. Clin 
Invest 1988; 260: 1259-1264. 
Schmidt EW, Rasche B, Ulmer B et al. Replacement 
therapy for alpha-1-protease inhibitor deficiency in P,Z 
subjects with -chronic obstructive lung disease. Am- J 
Med 1988: 84 (suvvl 5A): 63-69. 
Hubbard kc, ‘Brantly ML, Sellers SE, Mitchell ME, 
Crystal RG. Anti-neutrophil-elastase defences of the 
lower respiratory tract in al-antitrypsin deficiency 
directly augmented with an aerosol of al-antitrypsin. 
Ann Intern Med 1989; 111: 206212. 
Hubbard RC, McElvany NG, Sellers SE, Healy JT, 
Czerski DB, Crystal RG. Recombinant DNA-produced 
alpha 1-antitrypsin administered by aerosol augments 
lower respiratory tract antineutrophil elastase defences 
in individuals with alpha 1-antitrypsin deficiency. J C/in 
Invest 1989; 84: 1349-1354. 
Hubbard RC, Crystal RG. Strategies for aerosol 
therapy of alpha I-antitrypsin deficiency by the aerosol 
route. Lung 1990; 168 (suppl): 5655578. 
Stockley R A, Grant RA, Llewellyn-Jones CG, Hill SL, 
Burnett D. Neutrophil formyl-peptide receptors. 
Relationship to peptide-induced responses and emphy- 
sema. Am J Respir Crit Care Med 1994; 149 (2 pt 1): 
464468. 
Burnett D, Chamba A, Hill SL, Stockley RA. Neu- 
trophils from subjects with chronic obstructive lung 
disease show enhanced chemotaxis and extracellular 
proteolysis. Lancet 1987; 2: 104331046. 
Rosenfeld MA, Siegfried W, Yoshimura K et al. 
Adenovirus-mediated transfer of a recombinant 
al-antitrypsin gene to the lung epithelium in vivo. 
Science 1991; 252: 431434. 
22 BALR Symposium 
62. Barnes PJ, Pauwels RA. Theophylline in the manage- 83. Jager-Waldau R. Feasibility of drug delivery to the 
ment of asthma: time for reappraisal? Eur Respir J respiratory tract by a mechanical spray pump. J Aerosol 
1994; 7: 579-591. Med 1994; I: 147-154. 
63. Barnes PJ. Antiinflammatory therapy for asthma. Ann 84. Jager-Waldau R, Mehring H, Wiggins JD. A mechani- 
Rev Med 1993; 44: 21-50. cal micro spray pump: an alternative to propellant 
64. Barnes PJ, Chung KF. Questions about &agonists driven devices? J Aerosol Med 1994; I: 189-192. 
in asthma therapy. Trends Pharmacol Sci 1992; 13: 85. Jlger-Waldau R, Mehring R, Wiggins JD. Feasibility of 
2&23. a low dosage dynamic powder dispenser for drug deliv- 
65. Pavord ID, Tattersfield AE. Bronchoprotective role ery to the lungs. J Aerosol Med 1994; 7: 205-208. 
for endogenous prostaglandin E,. Lancet 1995; 345: 86. Cambrey AD, Harrison NK, Dawes KE et al. Increased 
435438. levels of endothelin 1 in bronchoalveolar lavage fluid 
66. Torphy TJ. b-Adrenoceptors, CAMP and airway from patients with systemic sclerosis contribute to 
smooth muscle relaxation: challenges to the dogma. fibroblast mitogenic activity in vitro. Am J Respir Cell 
Trends Pharmacol Sci 1994; 15: 37&374. Mol Biol 1994; 11: 439445. 
67. Black JL, Barnes PJ. Potassium channels and airway 87. Harrison NK. Cambrev AD. Mvers AR et al. Insulin- 
function: new therapeutic approaches. Thorax 1990; 45: 
213-218. 
68. Olesen S-P. Activators of large-conductance Ca’+- 
dependent K’ channels. Exp Opin Invest Drugs 1994; 3: 
1181-1188. 
like growth factor-l is-partially*responsible for fibro- 
blast proliferation induced by bronchoalveolar lavage 
fluid from patients with systemic sclerosis. Clin Sci 
1994; 86: 141-148. 
69. Edwards G, Niederste-Hollenberg A, Schneider J, 
Noak T, Weston AH. Ion channel modulation by NS 
1619, the putative BK,, channel opener, in vascular 
smooth muscle. Br J Pharmacol 1994; 113: 1538-1547. 
70. Chung KF, Barnes PJ. Role of inflammatory mediators 
in asthma. Br Med Bull 1992; 48: 135-148. 
71. Spence DPS, Johnston SL, Calverley PMA et al. The 
effect of the orally active platelet activating factor 
antagonist in the treatment of asthma. Am J Respir Crir 
Care Med 1994; 149: 1142-l 148. 
72. Kuitert LM, Angus RM, Barnes NC et al. A placebo- 
controlled study of a novel potent PAF antagonist, 
modipafant, in clinical asthma. Am J Respir Crit Care 
Med 1995; 151: 1331-1335. 
73. Chung KF. Leukotriene receptor antagonist and bio- 
synthesis inhibitors: potential breakthrough in asthma 
therapy. Eur Respir J 1995; 8: 1203-1213. 
74. Spector SL, Smith LJ, Glass M et al. Effects of 6 weeks 
of therapy with oral doses of ICI 204,219, a leukotriene 
D4 receptor antagonist, in subjects with bronchial 
asthma. Am J Respir Crit Care Med 1994; 150: 618-623. 
75. Barnes PJ, Pedersen S. Efficacy and safety of inhaled 
corticosteroids in asthma. Am Rev Respir Dis 1993; 14% 
Sl-S26. 
76. Brattsand R, Axelsson BI. New inhaled glucocorticos- 
teroids. In: Barnes PJ, ed. New Drugs for-Asthma, Vol. 
2. London: PJ. IBC Technical Services Limited. 1992. 
pp. 193-208. 
77. Barnes PJ, Adcock I. Anti-inflammatory actions of 
steroids: molecular mechanisms. Trends Pharmacol Sci 
1993; 14: 436441. 
78. Dent G, Giembycz MA. Selective phosphodiesterase 
inhibitors in the therapy of asthma. Clin Immuno- 
therapies 1995; 3: 4233437. 
79. Crompton GK. The adult patient’s difficulties with 
inhalers. Lung 1990; 168 (suppl): 658-662. 
80. Rogers DF, Ganderton D. Determining equivalence of 
inhaled medications. Respir Med 1995; 89: 2533261. 
81. Newman SP. Delivery systems. In: Barnes PJ, ed. New 
Drugs for Asthma, Vol. 2. London: IBC Technical 
Services Limited, 1992, pp. 245-257. 
82. Newman SP, Clarke SW. Bronchodilator delivery from 
Gentlehaler, a new low-velocity pressurised aerosol 
inhaler. Chest 1993; 103: 1442-1446. 
88 
89. 
90. 
91. 
92. 
93. 
94. 
95. 
96. 
97. 
98. 
99. 
Gray AJ, Reeves JT, Harrison NK, Winlove P, Laurent 
GJ. Growth factors for human fibroblasts in the solute 
remaining after clot formation. J Cell Sci 1990; 96: 
271-274. 
Brdekelmann TJ, Limper AH, Colby TV, McDonald 
JA. Transforming growth factor beta 1 is present at 
sites of extracellular matrix gene expression in human 
pulmonary fibrosis. Proc Nat1 Acad Sci USA. 1991; 88: 
6642-6646. 
Gauldie J, Jordana M, Cox G. Cytokines and 
pulmonary fibrosis. Thorax 1993; 48: 931-935. 
Corrin B, Butcher D, McAnulty RJ et al. Immuno- 
histochemical localization of transforming growth 
factor-beta 1 in the lungs of patients with systemic 
sclerosis, cryptogenic fibrosing alveolitis and other lung 
disorders. Histopathology 1994; 24: 145-150. 
Donnelly SC, Strieter RM, Kunkel SL et al. Interleukin 
8 and development of adult respiratory distress syn- 
drome in at-risk patient groups. Lancer 1993; 341: 
6433647. 
Damas P, Reuter A, Gysen P, Demonti J, Lamy M, 
Franchimont P. Tumour necrosis factor and 
interleukin-1 serum levels during severe sepsis in 
humans. Crit Care Med 1989; 17: 975-978. 
Miller AB, Foley NM, Singer M, Johnson N MCI, 
Meager A, Rook GAW. Tumour necrosis factor in 
bronchopulmonary secretions of patients with adult 
respiratory distress syndrome. Lancet 1989; ii: 7 12-7 14. 
Piguet PF, Ribaux C, Karpuz V, Grau GE, Kapanci Y. 
Expression and localisation of tumour necrosis factor- 
alpha and its mRNA in idiopathic pulmonary fibrosis. 
Am J Path01 1993; 143: 651-655. 
Piguet PF, Collart Ma, Grau GE, Sappino A-P, Vassalli 
P. Requirement of tumour necrosis factor for develop- 
ment of silica-induced pulmonary fibrosis. Nature 1990; 
344: 245-247. 
Piguet PF, Vesin C. Treatment by human recombinant 
soluble TNF receptor of pulmonary fibrosis induced by 
bleomycin or silica in mice. Eur Respir J 1994; 7: 
515-518. 
Gearing AJH, Beckett P, Christodoulou M er al. 
Processing of tumour necrosis factor- precursor by 
metalloproteinases. Nature 1994; 370: 555-557. 
McGeehan GM, Becherer JD, Bast RC ef al. Regula- 
tion of tumour necrosis factor-processing by a metallo- 
proteinase inhibitor. Nature 1994; 370: 558-561. 
BALR Symposium 23 
100. 
101. 
102. 
103. 
104. 
105. 
106. 
107. 
108. 
109. 
110. 
Giri SN, Hyde DM, Hollinger MA. Effect of antibody 
to transforming growth factor /I on bleomycin induced 
accumulation of lung collagen in mice. Thorax 1993; 
48: 959-966. 
Laurent GJ, Coker RK, McAnulty RJ. TGF-/? anti- 
bodies: a novel treatment for pulmonary fibrosis? 
Thorax 1993; 48: 953-954. 
Editorial. Lung Transplantation. Lancer 1992; 339: 
1021-1022. 
Tsang V, Hodson ME, Yacoub MH. Lung transplan- 
tation for cystic fibrosis. Brit Med BUN 1992; 48: 
949-97 1. 
Hosenpud JD, Richard JN, Breen TJ, Daily OP. The 
registry of the international society for heart and lung 
transplantation: eleventh official report-1994. J Heart 
Lung Transplant 1994; 13: 561-570. 
Levy RD, Guerraty AJ, Yacoub MH. Prolonged sur- 
vival after heart-lung transplantation in systemic lupus 
erythematosus. Chest 1993; 104: 1903-1905. 
Kramer MR. Bronchiolitis obliterans following heart- 
lung and lung transplantation. Respir Med 1994; 88: 
9-15. 
Clelland CA, Higenbottam TW, Stewart S, Scott JP, 
Wallwork J. The histological changes in transbron- 
chial biopsy after treatment of acute lung rejection in 
heart-lung transplant. J Pathol 1990; 161: 105-l 12. 
Adams DH, Cochrane AD, Khaghani A, Smith JD, 
Yacoub MH. Retransplantation in heart-lung 
recipients with obliterative bronchiolitis. J Thorac 
Cardiovasc Surg 1994; 107: 45W59. 
Novick RJ, Andreassian B, Schaffers HJ et al. Pulmo- 
nary retransplantation for obliterative bronchiolitis - 
intermediate-term results of a North American- 
European series. J Thorac Cardiovasc Surg 1994; 107: 
755-763. 
Whitehead B, Rees P, Sorensen, et al. Incidence of 
obliterative bronchiolitis after heart-lung transplan- 
111. 
112. 
113. 
114. 
115. 
116. 
117. 
118. 
119. 
tation in children. J Heart Lung Transplant 1993; 12: 
903-908. 
Sharples LD, Scott JP, Dennis C et al. Risk factors for 
survival following combined heart-lung transplan- 
tation. Transplantation 1994; 57: 218223. 
Thomson AW, Starzl TE. New immunosuppressive 
drugs: mechanistic insights and potential therapeutic 
advances. Immunol Rev 1993; 136: 71-98. 
Starzl TE. Cell migration and chimerism - a unifying 
concept in transplantation - with particular reference 
to HLA matching and tolerance induction. Transplan- 
tation Proc 1993; 25: 8-12. 
Starzle TE, Demetris AJ, Murase N, Thomson AW, 
Truce M, Ricordi C. Donor cell chimerism permitted 
by immunosuppressive drugs: a new view of organ 
transplantation. Zmmunol Today 1993; 14: 326-332. 
Springall DR, Polak JM, Howard L et al. Persistence 
of intrinsic neurones and possible phenotypic changes 
after extrinsic denervation of human respiratory tract 
by heart-lung transplantation. Am Rev Respir Dis 
1990; 141: 1538-1546. 
Herve P, Picard N, Le Roy Ladurie M et al. Lack of 
bronchial hyperresponsiveness to methacholine and to 
isocapnic dry air hyperventilation in heart/lung and 
double-lung transplant. Am Rev Respir Dis 1992; 145: 
1503-1505. 
Rogers DF, O’Connor BJ. Airway hyperresponsive- 
ness: relation to asthma and inflammation? Thorax 
1993; 48: 1095 1096. 
Hathaway TJ, Higenbottam TW, Morison JFJ, 
Clelland CA. Wallwork J. Effects of inhaled cansaicin 
in heart-lung transplant patients and asthmatic 
subjects. Am Rev Respir Dis 1993; 148: 123331237. 
Corris PA, Dark JH. Aetiology of asthma: lessons 
from lung transplantation. Lancet 1993; 341: 
1369-1371. 
